Comparative Pharmacology
Head-to-head clinical analysis: AMBRISENTAN versus FILSPARI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBRISENTAN versus FILSPARI.
AMBRISENTAN vs FILSPARI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist (ERA) that selectively binds to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle, blocking endothelin-1-mediated vasoconstriction and proliferation.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
10 mg orally once daily, with or without food, for patients not receiving cyclosporine. For patients receiving cyclosporine, reduce dose to 5 mg once daily.
200 mg orally once daily, with or without food.
None Documented
None Documented
Clinical Note
moderateAmbrisentan + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Methylphenidate
"Ambrisentan may decrease the antihypertensive activities of Methylphenidate."
Clinical Note
moderateAmbrisentan + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ambrisentan."
Clinical Note
moderateAmbrisentan + Erythromycin
Terminal elimination half-life is approximately 9 hours (range 4–20 hours) in healthy subjects; no significant accumulation is observed with once-daily dosing.
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Primarily via nonrenal pathways, with fecal excretion accounting for approximately 77% of a radiolabeled dose (as unchanged drug and metabolites) and renal excretion for about 22% (mostly as metabolites).
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Category C
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist / ARB
"The metabolism of Erythromycin can be decreased when combined with Ambrisentan."